Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Hep B, Functional Cure Likely Means Two-Part Combination Process

Executive Summary

While current HBV drugs work well to suppress the virus, combination success in HIV and HCV is leading biopharmas to seek a multi-part approach to suppressing and clearing the virus, with limited-term therapy.

You may also be interested in...



RNAi Partners Vie To Lead Race To Cure Hepatitis B

At EASL 2020, four partnerships updated RNA-interference or antisense efforts to reduce hep B surface antigen, believed to lead to functional cure of the virus. One analyst sees J&J/Arrowhead as the early leader.

Finance Watch: Here Come The IPOs Again As Bellus Raises $70m And Vir Joins The Queue

Public Company Edition: Bellus launched the first biopharma IPO in the US since mid-July and Vir Biotechnology, run by former Biogen CEO George Scangos, wants to raise $100m. Also, Turning Point's $202.5m offering and Zafgen's strategic review.

J&J Bets Big On Arrowhead’s Early Promise In Hepatitis B

The pharma is paying $250m up front for worldwide rights to Arrowhead’s Phase I/II RNAi candidate. Arrowhead says letting J&J take the lead on HBV enables it to focus on other pipeline programs it can bring to market itself.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel